SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) — ?Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines,?today recapped 2026 successes to date and provided an update on the Company’s upcoming milestones.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
